Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.

NCT04207580 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2020-03-13
Last updated
2026-03-13

Condition(s) studied

Idiopathic Nephrotic Syndrome

Investigational drug(s) / intervention(s)

Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,

Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,: The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients. A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment).

Study summary

Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies.

The main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Patient under 18 years of age * With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018 * Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology * Residing in France * Consent signed by parents and patient's agreement to participate (if of age) * Affiliated to a social security system. Exclusion Criteria: * Refusal of the patient or legal representatives to participate in the cohort

Primary outcome measure(s)

  • Number of cases included in the cohort and description of their characteristics — 2 years
    * Number of followed cases, gender, and age * Geographical localization of followed cases * Progressive disease pattern (relapses, corticosteroid dependence, other treatments used) * Serious side effects related to treatment

Trial sites (48)

FacilityCityRegionStatus
CH d'Agen Agen France Recruiting
CHU d'Amiens Amiens France Recruiting
CHU d'Auxerre Auxerre France Recruiting
CH de la côte basque Bayonne France Recruiting
CHU de Besançon Besançon France Recruiting
CHU de Boredeaux Bordeaux France Recruiting
CHU de Brest Brest France Recruiting
HCL Lyon Bron France Recruiting
CH de Chambéry Chambéry France Recruiting
CHU de Clermont Ferrand Clermont-Ferrand France Recruiting
CHU de Dijon Dijon France Recruiting
CH du Val d'Ariège Foix France Recruiting
CH de la Rochelle La Rochelle France Recruiting
CHU de Grenoble La Tronche France Recruiting
CH de Versaille Le Chesnay France Recruiting
CHU de Lille - Hôpital Jeanne de Flandre Lille France Recruiting
Limoges Hospital Limoges France Recruiting
CHU de Marseille - Timone enfants Marseille France Recruiting
CH de Macon Mâcon France Recruiting
CHU de Montpellier - Hôpital Arnaud de Villeneuve Montpellier France Recruiting
CHU de Nancy Nancy France Recruiting
CHU de Nantes Nantes France Recruiting
CHU de Nice - Hopital Larchet Nice France Recruiting
CHU de Nimes Nîmes France Recruiting
AP-HP Trousseau Paris France Recruiting
AP-HP Robert Debré Paris France Recruiting
AP-HP Necker Paris France Recruiting
CH de Pau Pau France Recruiting
CH de Perpignan Perpignan France Recruiting
CH de Périgueux Périgueux France Recruiting
CHU de Poitiers Poitiers France Recruiting
CH d'Annecy Pringy France Recruiting
CHU de Reims Reims France Recruiting
CHU de Rennes Rennes France Recruiting
CH de Roanne Roanne France Not Yet Recruiting
CH de Roubaix Roubaix France Recruiting
CHU de Rouen Rouen France Recruiting
CHU de Saint-Etienne Saint-Priest-en-Jarez France Recruiting
CH de Sallanches Sallanches France Terminated
CHRU de Strasbourg Strasbourg France Recruiting

+ 8 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04207580 on ClinicalTrials.gov ↗ ← All trials in France